DAK-Gesundheit awards €218 million generic pharmaceutical framework deal

DAK-Gesundheit, on behalf of six German statutory health insurance funds (Ersatzkassen), has awarded a multi-lot framework agreement for generic pharmaceutical products worth up to €218 million over two years. The framework, divided into 168 lots covering various active substances, has been awarded to numerous pharmaceutical companies including PUREN Pharma, Viatris, Glenmark, and many others.

Introduction

Germany's statutory health insurance system relies on competitive procurement to manage pharmaceutical costs. Under § 130a Abs. 8 SGB V, health insurance funds are required to conclude discount agreements with pharmaceutical companies for generic medicines. The "Generika-Ersatzkassen 29" framework represents one of the largest such procurements in Germany.

Coordinated by DAK-Gesundheit on behalf of six Ersatzkassen (replacement funds)—DAK-Gesundheit, TK, KKH, HEK, hkk, and BARMER—the framework covers 168 lots of active substances, running from January 2027 to December 2028, with a total estimated value of €218 million.

This procurement ensures that millions of insured patients across Germany have access to cost-effective generic medicines through the statutory health insurance system.

Why This Contract Matters

Generic medicines account for a significant portion of pharmaceutical spending in Germany. By concluding discount agreements with pharmaceutical companies, health insurance funds secure rebates on the cost of medicines dispensed to their insured members.

This framework matters because it:

• Covers essential medicines: 168 lots across a wide range of therapeutic areas
• Delivers cost savings: Discount agreements reduce pharmaceutical expenditure for health insurance funds
• Ensures supply security: Framework agreements guarantee availability of key medicines for insured patients
• Coordinates multiple funds: Six Ersatzkassen participate, leveraging collective buying power
• Involves extensive competition: Multiple pharmaceutical companies compete for individual lots

Contract Timeline

• Contract award notice published: 6 August 2026 (OJ S 150/2026)
• Previous notice referenced: 148015-2026
• Winner chosen: 6 July 2026
• Contract concluded: 6 July 2026
• Coverage start date: 1 January 2027
• Coverage end date: 31 December 2028 (with optional extensions)

Contract Overview

The contract is a framework agreement for active substance-related discount agreements pursuant to § 130a Abs. 8 SGB V. The framework covers 168 lots, each representing a specific active substance (or group of substances) with specific pharmaceutical forms.

Key features include:

• 168 lots: Individual lots for specific active substances and pharmaceutical forms
• Duration: 24 months (1 January 2027 – 31 December 2028)
• Optional extensions: Up to two six-month extensions (max 36 months)
• Evaluation: Price only (100% weighting)
• Total estimated value: €218,240,376.72 (excluding VAT)
• Framework type: Without reopening of competition
• Participants: 6 statutory health insurance funds (Ersatzkassen)

Key Contract Details

Detail	Information
Coordinating buyer	DAK-Gesundheit
Participating buyers	DAK-Gesundheit, TK, KKH, HEK, hkk, BARMER
Contract subject	Generic pharmaceutical products (CPV 33600000)
Procedure type	Open procedure
Legal basis	EU Directive 2014/24/EU
Total estimated value (ex-VAT)	€218,240,376.72
Number of lots	168
Contract duration	1 January 2027 – 31 December 2028 (up to 36 months with extensions)
EU funding	None
Covered by GPA	No
Winner chosen	6 July 2026
Contract signed	6 July 2026
Evaluation criteria	Price only (100%)
Framework type	Framework agreement without reopening of competition

Project Scope

The framework covers generic pharmaceutical products across 168 lots, divided into active substance groups. Each lot corresponds to a specific active substance with defined pharmaceutical forms (e.g., tablets, creams, solutions). The lots are structured according to therapeutic areas.

Sample Lots (Selected from 168)

• Lot 101: Mebeverin - A03AA04 (FTA / UTA)
• Lot 102: Mebeverin - A03AA04 (REK)
• Lot 103: Carglumsäure - A16AA05
• Lot 104: Acitretin - D05BB02
• Lot 105: Mometason - D07AC13 (CRE)
• Lot 107: Mometason - D07AC13 (SAL)
• Lot 108: Fesoterodin - G04BD11
• Lot 109: Prednisolon - H02AB06
• Lot 110: Ibandronsäure - M05BA06 (FTA)
• Lot 111: Ibandronsäure - M05BA06 (IFK)
• Lot 112: Morphin - N02AA01 (Oral unretardiert)
• Lot 113: Fentanyl - N02AB03 (LUT)
• Lot 114: Fentanyl - N02AB03 (SUT)
• Lot 115: Fentanyl - N02AB03 (TAB)
• Lot 116: Codein und Paracetamol - N02AJ06 (HKP / TAB)
• Lot 117: Codein und Paracetamol - N02AJ06 (SUP)
• Lot 118: Carbamazepin - N03AF01
• Lot 119: Levetiracetam - N03AX14 (GRA)
• Lot 120: Entacapon - N04BX02
• Lot 121: Diazepam - N05BA01 (TAB)
• Lot 122: Diazepam - N05BA01 (TEI)
• Lot 123: Acetylcystein - R05CB01
• Lot 124: Ebastin - R06AX22
• Lot 125: Lactulose - A06AD11
• Lot 126: Glimepirid - A10BB12
• Lot 127: Urapidil - C02CA06
• Lot 128: Furosemid - C03CA01
• Lot 129: Torasemid - C03CA04
• Lot 130: Hydrochlorothiazid und Triamteren - C03EA21
• Lot 131: Irbesartan und Hydrochlorothiazid - C09DA24
• Lot 132: Ganirelix - H01CC01
• Lot 133: Ibandronsäure - M05BA06 (IFE / ILO)
• Lot 134: Morphin - N02AA01 (ILO)
• Lot 135: Levetiracetam - N03AX14 (IFK)
• Lot 136: Zolpidem - N05CF02
• Lot 137: Escitalopram - N06AB10 (TEI)
• Lot 138: Beclometason - R03BA01
• Lot 139: Levocetirizin - R06AE09
• Lot 140: Ursodeoxycholsäure - A05AA02
• Lot 141: Acetylsalicylsäure - B01AC06
• Lot 142: Carvedilol - C07AG02
• Lot 143: Amlodipin - C08CA01
• Lot 144: Telmisartan - C09CA07
• Lot 145: Ezetimib - C10AX09
• Lot 146: Tamsulosin - G04CA02
• Lot 147: Valganciclovir - J05AB14
• Lot 148: Letrozol - L02BG04
• Lot 149: Apremilast - L04AA32
• Lot 150: Fingolimod - L04AE01
• Lot 151: Morphin - N02AA01 (Oral retardiert)
• Lot 152: Fentanyl - N02AB03 (PFT)
• Lot 153: Levetiracetam - N03AX14 (FTA)
• Lot 154: Escitalopram - N06AB10 (FTA / SMT)
• Lot 155: Bupropion - N06AX12
• Lot 156: Mometason - R01AD09

Further Lots (DAK / KKH Group)

• Lot 201: Mebeverin - A03AA04 (FTA / UTA) [TK/hkk/HEK]
• Lot 202: Mebeverin - A03AA04 (REK) [TK/hkk/HEK]
• Lot 203: Carglumsäure - A16AA05 [TK/hkk/HEK]
• Lot 204: Acitretin - D05BB02 [TK/hkk/HEK]
• Lot 205: Mometason - D07AC13 (CRE) [TK/hkk/HEK]
• Lot 207: Mometason - D07AC13 (SAL) [TK/hkk/HEK]
• Lot 208: Fesoterodin - G04BD11 [TK/hkk/HEK]
• Lot 209: Prednisolon - H02AB06 [TK/hkk/HEK]
• Lot 210: Ibandronsäure - M05BA06 (FTA) [TK/hkk/HEK]
• Lot 211: Ibandronsäure - M05BA06 (IFK) [TK/hkk/HEK]
• Lot 212: Morphin - N02AA01 (Oral unretardiert) [TK/hkk/HEK]
• Lot 213: Fentanyl - N02AB03 (LUT) [TK/hkk/HEK]
• Lot 214: Fentanyl - N02AB03 (SUT) [TK/hkk/HEK]
• Lot 215: Fentanyl - N02AB03 (TAB) [TK/hkk/HEK]
• Lot 216: Codein und Paracetamol - N02AJ06 (HKP / TAB) [TK/hkk/HEK]
• Lot 217: Codein und Paracetamol - N02AJ06 (SUP) [TK/hkk/HEK]
• Lot 218: Carbamazepin - N03AF01 [TK/hkk/HEK]
• Lot 219: Levetiracetam - N03AX14 (GRA) [TK/hkk/HEK]
• Lot 220: Entacapon - N04BX02 [TK/hkk/HEK]
• Lot 221: Diazepam - N05BA01 (TAB) [TK/hkk/HEK]
• Lot 222: Diazepam - N05BA01 (TEI) [TK/hkk/HEK]
• Lot 223: Acetylcystein - R05CB01 [TK/hkk/HEK]
• Lot 224: Ebastin - R06AX22 [TK/hkk/HEK]
• Lot 225: Lactulose - A06AD11 [TK/hkk/HEK]
• Lot 226: Glimepirid - A10BB12 [TK/hkk/HEK]
• Lot 227: Urapidil - C02CA06 [TK/hkk/HEK]
• Lot 228: Furosemid - C03CA01 [TK/hkk/HEK]
• Lot 229: Torasemid - C03CA04 [TK/hkk/HEK]
• Lot 230: Hydrochlorothiazid und Triamteren - C03EA21 [TK/hkk/HEK]
• Lot 231: Irbesartan und Hydrochlorothiazid - C09DA24 [TK/hkk/HEK]
• Lot 232: Ganirelix - H01CC01 [TK/hkk/HEK]
• Lot 233: Ibandronsäure - M05BA06 (IFE / ILO) [TK/hkk/HEK]
• Lot 234: Morphin - N02AA01 (ILO) [TK/hkk/HEK]
• Lot 235: Levetiracetam - N03AX14 (IFK) [TK/hkk/HEK]
• Lot 236: Zolpidem - N05CF02 [TK/hkk/HEK]
• Lot 237: Escitalopram - N06AB10 (TEI) [TK/hkk/HEK]
• Lot 238: Beclometason - R03BA01 [TK/hkk/HEK]
• Lot 239: Levocetirizin - R06AE09 [TK/hkk/HEK]
• Lot 240: Ursodeoxycholsäure - A05AA02 [TK/hkk/HEK]
• Lot 241: Acetylsalicylsäure - B01AC06 [TK/hkk/HEK]
• Lot 242: Carvedilol - C07AG02 [TK/hkk/HEK]
• Lot 243: Amlodipin - C08CA01 [TK/hkk/HEK]
• Lot 244: Telmisartan - C09CA07 [TK/hkk/HEK]
• Lot 245: Ezetimib - C10AX09 [TK/hkk/HEK]
• Lot 246: Tamsulosin - G04CA02 [TK/hkk/HEK]
• Lot 247: Valganciclovir - J05AB14 [TK/hkk/HEK]
• Lot 248: Letrozol - L02BG04 [TK/hkk/HEK]
• Lot 249: Apremilast - L04AA32 [TK/hkk/HEK]
• Lot 250: Fingolimod - L04AE01 [TK/hkk/HEK]
• Lot 251: Morphin - N02AA01 (Oral retardiert) [TK/hkk/HEK]
• Lot 252: Fentanyl - N02AB03 (PFT) [TK/hkk/HEK]
• Lot 253: Levetiracetam - N03AX14 (FTA) [TK/hkk/HEK]
• Lot 254: Escitalopram - N06AB10 (FTA / SMT) [TK/hkk/HEK]
• Lot 255: Bupropion - N06AX12 [TK/hkk/HEK]
• Lot 256: Mometason - R01AD09 [TK/hkk/HEK]

Further Lots (BARMER Group)

• Lot 301: Mebeverin - A03AA04 (FTA / UTA) [BARMER]
• Lot 302: Mebeverin - A03AA04 (REK) [BARMER]
• Lot 303: Carglumsäure - A16AA05 [BARMER]
• Lot 304: Acitretin - D05BB02 [BARMER]
• Lot 305: Mometason - D07AC13 (CRE) [BARMER]
• Lot 307: Mometason - D07AC13 (SAL) [BARMER]
• Lot 308: Fesoterodin - G04BD11 [BARMER]
• Lot 309: Prednisolon - H02AB06 [BARMER]
• Lot 310: Ibandronsäure - M05BA06 (FTA) [BARMER]
• Lot 311: Ibandronsäure - M05BA06 (IFK) [BARMER]
• Lot 312: Morphin - N02AA01 (Oral unretardiert) [BARMER]
• Lot 313: Fentanyl - N02AB03 (LUT) [BARMER]
• Lot 314: Fentanyl - N02AB03 (SUT) [BARMER]
• Lot 315: Fentanyl - N02AB03 (TAB) [BARMER]
• Lot 316: Codein und Paracetamol - N02AJ06 (HKP / TAB) [BARMER]
• Lot 317: Codein und Paracetamol - N02AJ06 (SUP) [BARMER]
• Lot 318: Carbamazepin - N03AF01 [BARMER]
• Lot 319: Levetiracetam - N03AX14 (GRA) [BARMER]
• Lot 320: Entacapon - N04BX02 [BARMER]
• Lot 321: Diazepam - N05BA01 (TAB) [BARMER]
• Lot 322: Diazepam - N05BA01 (TEI) [BARMER]
• Lot 323: Acetylcystein - R05CB01 [BARMER]
• Lot 324: Ebastin - R06AX22 [BARMER]
• Lot 325: Lactulose - A06AD11 [BARMER]
• Lot 326: Glimepirid - A10BB12 [BARMER]
• Lot 327: Urapidil - C02CA06 [BARMER]
• Lot 328: Furosemid - C03CA01 [BARMER]
• Lot 329: Torasemid - C03CA04 [BARMER]
• Lot 330: Hydrochlorothiazid und Triamteren - C03EA21 [BARMER]
• Lot 331: Irbesartan und Hydrochlorothiazid - C09DA24 [BARMER]
• Lot 332: Ganirelix - H01CC01 [BARMER]
• Lot 333: Ibandronsäure - M05BA06 (IFE / ILO) [BARMER]
• Lot 334: Morphin - N02AA01 (ILO) [BARMER]
• Lot 335: Levetiracetam - N03AX14 (IFK) [BARMER]
• Lot 336: Zolpidem - N05CF02 [BARMER]
• Lot 337: Escitalopram - N06AB10 (TEI) [BARMER]
• Lot 338: Beclometason - R03BA01 [BARMER]
• Lot 339: Levocetirizin - R06AE09 [BARMER]
• Lot 340: Ursodeoxycholsäure - A05AA02 [BARMER]
• Lot 341: Acetylsalicylsäure - B01AC06 [BARMER]
• Lot 342: Carvedilol - C07AG02 [BARMER]
• Lot 343: Amlodipin - C08CA01 [BARMER]
• Lot 344: Telmisartan - C09CA07 [BARMER]
• Lot 345: Ezetimib - C10AX09 [BARMER]
• Lot 346: Tamsulosin - G04CA02 [BARMER]
• Lot 347: Valganciclovir - J05AB14 [BARMER]
• Lot 348: Letrozol - L02BG04 [BARMER]
• Lot 349: Apremilast - L04AA32 [BARMER]
• Lot 350: Fingolimod - L04AE01 [BARMER]
• Lot 351: Morphin - N02AA01 (Oral retardiert) [BARMER]
• Lot 352: Fentanyl - N02AB03 (PFT) [BARMER]
• Lot 353: Levetiracetam - N03AX14 (FTA) [BARMER]
• Lot 354: Escitalopram - N06AB10 (FTA / SMT) [BARMER]
• Lot 355: Bupropion - N06AX12 [BARMER]
• Lot 356: Mometason - R01AD09 [BARMER]

About the Contracting Authority

DAK-Gesundheit is one of Germany's largest statutory health insurance funds (Gesetzliche Krankenkasse). In this procurement, DAK-Gesundheit acts as the coordinating buyer on behalf of six Ersatzkassen (replacement funds):

• DAK-Gesundheit – Germany's oldest health insurance fund
• TK-Techniker Krankenkasse – One of the largest health insurance funds in Germany
• KKH - Kaufmännische Krankenkasse – Commercial health insurance fund
• HEK - Hanseatische Krankenkasse – Hanseatic health insurance fund
• hkk - Handelskrankenkasse – Trade health insurance fund
• BARMER – One of Germany's largest health insurance funds

The procurement is conducted under the legal framework of § 130a Abs. 8 SGB V, which mandates discount agreements for generic medicines.

About the Winning Companies

The framework has been awarded to numerous pharmaceutical companies, with multiple winners per lot. Key winners include:

• PUREN Pharma GmbH & Co. KG – Large German pharmaceutical company (Netherlands-owned) – Won 23 lots
• Viatris Healthcare GmbH – Large German pharmaceutical company (French/German-owned) – Won 3 lots
• Recordati Rare Diseases Germany GmbH – Large German pharmaceutical company – Won 3 lots
• Glenmark Arzneimittel GmbH – Large German pharmaceutical company – Won 14 lots
• BG ALIUD / STADAPHARM GbR – Large German pharmaceutical consortium – Won 30 lots
• BG Hexal 1A Pharma GbR – Large German pharmaceutical consortium – Won 32 lots
• Accord Healthcare GmbH – Large German pharmaceutical company (UK-owned) – Won 5 lots
• Phoenix Labs Unlimited Company – Large Irish pharmaceutical company – Won 4 lots
• Grünenthal GmbH – Large German pharmaceutical company – Won 3 lots
• HEC Pharm GmbH – Large German pharmaceutical company (Chinese-owned) – Won 3 lots
• Micro Labs GmbH – Large German pharmaceutical company (Indian-owned) – Won 10 lots
• BG Heumann / Heunet GbR – Large German pharmaceutical consortium – Won 15 lots
• Zentiva Pharma GmbH – Large German pharmaceutical company (Luxembourg-owned) – Won 14 lots
• BG TEVA ratiopharm GbR – Large German pharmaceutical consortium – Won 17 lots
• Betapharm Arzneimittel GmbH – Large German pharmaceutical company (Indian-owned) – Won 7 lots
• Medical Valley Invest AB – Large Swedish pharmaceutical company – Won 5 lots
• And many others

Contract values are unpublished (justified as trade secrets).

Procurement Analysis

• Procedure: An open procedure was used, allowing any interested economic operator to submit a tender.
• Competition: Competition varied by lot, with 0-13 bidders per lot. Some lots received no bids and were not awarded.
• Evaluation criteria: Price only (100% weighting). This is standard for discount agreements under German pharmaceutical procurement law.
• Framework structure: Framework agreements without reopening of competition.
• Foreign Subsidies Regulation (FSR): All awarded lots had notifications submitted with administrative closure of FSR preliminary review procedures.
• Lots not awarded: Several lots received no bids or were cancelled due to technical/procedural errors (see results below).

Additional Procurement Facts

• The contract is not covered by the WTO Government Procurement Agreement (GPA).
• No EU funds were used for this procurement.
• The procurement was not accelerated.
• No dynamic purchasing system was used.
• Framework agreements without reopening of competition were used.
• Each lot was awarded separately to one or multiple suppliers (3-5 per lot typically).
• No subcontracting was declared by any winner.
• Disputes or review requests fall to the Vergabekammer des Bundes beim Bundeskartellamt.
• Contract values are not published (justified as trade secrets).

Market & Industry Perspective

The German generic pharmaceutical market is one of the largest in Europe, with significant public procurement through statutory health insurance funds. The Ersatzkassen framework is a key procurement mechanism, driving competition and cost savings in the pharmaceutical sector.

Key trends in this market include:

• Price pressure: Price-only evaluation creates intense competition, driving down pharmaceutical costs for health insurance funds
• Consolidation: Bidding consortia (Bietergemeinschaften) are common, allowing smaller companies to compete for larger lots
• International ownership: Many winning companies have international parent companies (Netherlands, UK, India, China, Luxembourg, Ireland, Sweden)
• Foreign Subsidies Regulation (FSR): All awarded lots have undergone FSR review, reflecting the EU's focus on foreign subsidies in procurement
• Supply security: Framework agreements ensure stable supply of generic medicines to insured patients

Economic Significance

At an estimated value of €218 million over two years (with optional extensions), this framework represents a significant portion of pharmaceutical spending for the participating health insurance funds. The discount agreements secured through this procurement will reduce pharmaceutical expenditure, ultimately benefiting insured members through lower contributions.

For the winning pharmaceutical companies, the framework provides stable, predictable revenue streams over the contract period. The multi-lot structure allows companies to bid for specific active substances where they have competitive advantages.

Future Procurement Opportunities

With the framework now in place through December 2028 (potentially extended to December 2029), future opportunities include:

• Contract extensions: Up to two six-month extensions (potentially through December 2029)
• Re-tender: The next Ersatzkassen generics framework (Generika-Ersatzkassen 30) will be tendered in 2028-2029
• Other health insurance funds: Similar frameworks are conducted by other German health insurance funds
• Additional active substances: New active substances may be added to future frameworks

Opportunities for Suppliers

While this framework is now awarded, future opportunities exist for pharmaceutical companies:

• Bidding consortia: Forming consortia (Bietergemeinschaften) can enable smaller companies to compete for larger lots
• Competitive pricing: Price-only evaluation means competitive pricing is paramount
• International presence: Companies with international parent companies can leverage global supply chains for cost advantages
• FSR compliance: Ensuring compliance with the Foreign Subsidies Regulation is essential for participation

What Businesses Should Watch

• Re-tendering of the Ersatzkassen generics framework (Generika-Ersatzkassen 30)
• Similar frameworks from other German health insurance funds (AOK, IKK, etc.)
• Changes to German pharmaceutical procurement law (SGB V, AMG)
• EU Foreign Subsidies Regulation (FSR) developments
• New active substances and therapeutic areas

GermanyTender Procurement Intelligence

This framework is a textbook example of large-scale pharmaceutical procurement in Germany. Several features are notable:

• Scale: 168 lots with a total estimated value of €218 million
• Price-only evaluation: Standard for discount agreements, reflecting the statutory requirement to secure cost savings
• Multi-supplier model: Most lots have 3-5 winners, ensuring supply security and competition
• Consortia bidding: Many lots were won by consortia (Bietergemeinschaften), allowing smaller companies to compete effectively
• FSR compliance: All awarded lots have undergone FSR review, reflecting the EU's focus on foreign subsidies

The participation of major international pharmaceutical companies (including companies owned in the Netherlands, UK, India, China, Luxembourg, Ireland, and Sweden) highlights the global nature of the generic pharmaceutical market.

Supplier Takeaways

• Price is the sole evaluation criterion—competitive pricing is essential
• Forming consortia can enable smaller companies to compete for larger lots
• Ensure FSR compliance for participation in EU procurement
• Monitor re-tendering cycles (typically every 2-3 years)
• Build relationships with health insurance funds to understand their procurement strategies
• Consider international partnerships to leverage global supply chains

Key Takeaways

• DAK-Gesundheit coordinated a €218 million generics framework on behalf of six Ersatzkassen
• 168 lots covering various active substances and pharmaceutical forms
• Price-only evaluation (100% weighting)
• Winners include 20+ pharmaceutical companies and consortia
• Contract duration: January 2027 – December 2028 (up to 36 months with extensions)
• FSR compliance required for all lots
• Some lots not awarded due to no bids or procedural errors
• Contract values not published (trade secrets)

Conclusion

This framework agreement represents a significant procurement in the German generic pharmaceutical market. By coordinating the purchasing power of six Ersatzkassen, DAK-Gesundheit has secured discount agreements across 168 lots, ensuring cost-effective access to generic medicines for millions of insured patients.

The framework's structure—with multiple winners per lot, consortia bidding, and price-only evaluation—reflects the competitive nature of the German pharmaceutical market. The participation of both German and international companies highlights the global nature of the generic pharmaceutical supply chain.

As the framework runs through 2028 (with potential extensions), the winning pharmaceutical companies will provide essential medicines to the German healthcare system, while health insurance funds benefit from cost savings that help manage pharmaceutical expenditure.

Frequently Asked Questions

Q: What is Generika-Ersatzkassen 29?

Ans: A framework agreement for discount contracts on generic pharmaceutical products, coordinated by DAK-Gesundheit on behalf of six German statutory health insurance funds (Ersatzkassen).

Q: How many lots are there?

Ans: 168 lots, each covering a specific active substance with defined pharmaceutical forms.

Q: Who are the participating health insurance funds?

Ans: DAK-Gesundheit, TK-Techniker Krankenkasse, KKH, HEK, hkk, and BARMER.

Q: What is the total value of the framework?

Ans: €218,240,376.72 (excluding VAT), estimated.

Q: What was the evaluation criterion?

Ans: Price only (100% weighting).

Q: How long is the framework?

Ans: 24 months (1 January 2027 – 31 December 2028), with up to two six-month extensions (max 36 months).

Q: Are contract values published?

Ans: No, contract values are not published (justified as trade secrets).

Q: What is the Foreign Subsidies Regulation (FSR)?

Ans: An EU regulation that requires review of foreign subsidies that may distort competition in the internal market.

Q: Which companies won?

Ans: Over 20 pharmaceutical companies and consortia, including PUREN Pharma, Viatris, Glenmark, BG ALIUD/STADAPHARM, BG Hexal 1A Pharma, Accord Healthcare, Phoenix Labs, Grünenthal, HEC Pharm, Micro Labs, BG Heumann/Heunet, Zentiva, BG TEVA ratiopharm, and many others.

Source: EU Official Journal, Contract Award Notice 544832-2026, OJ S 150/2026, published 6 August 2026.